Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | CSF1R |
| Variant | positive |
| Impact List | unknown |
| Protein Effect | unknown |
| Gene Variant Descriptions | CSF1R positive indicates the presence of CSF1R mRNA and/or protein. |
| Associated Drug Resistance | |
| Category Variants Paths |
CSF1R positive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CSF1R positive | Hodgkin's lymphoma | sensitive | Sorafenib | Preclinical | Actionable | In a preclinical study, Nexavar (sorafenib) inhibited CSF1R phosphorylation and induced apoptosis in Hodgkin's lymphoma cells in culture (PMID: 21517818) | 21517818 |
| CSF1R positive | Hodgkin's lymphoma | not applicable | N/A | Clinical Study | Prognostic | In multiple clinical studies, elevated levels of CSF1R expression were associated with a worse survival in patients with Hodgkin's lymphoma (PMID: 24619759, PMID: 26066800, PMID: 22955918). | 24619759 26066800 22955918 |
| CSF1R positive | chronic myelomonocytic leukemia | predicted - sensitive | NMS-P088 | Preclinical - Patient cell culture | Actionable | In a preclinical study, NMS-P088 inhibited proliferation of Csf1r-expressing blasts derived from chronic myelomonocytic leukemia patients (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1324). | detail... |
| CSF1R positive | head and neck squamous cell carcinoma | predicted - sensitive | Cabozantinib + Pembrolizumab | Phase II | Actionable | In a Phase II trial, Cometriq (Cabometyx, cabozantinib) and Keytruda (pemrolizumab) combination therapy was safe and resulted in a median progression-free survival of 12.8 mo and median overall survival (mOS) of 27.7 mo in patients with recurrent or metastatic head and neck squamous cell carcinoma, higher baseline density of CSF1R-positive cells correlated with improved OS (HR 6.87, p=0.040), with mOS not reached in high and 17.8 mo in low CSF1R-positive patients (PMID: 39167623; NCT03468218). | 39167623 |